Pre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort study

Abstract Beta-blockers have been associated with decreased cancer mortality. However, evidence for lung cancer is sparse and reported beneficial effects might be based on biased analyses. In this so far largest study we investigated the association between β-blocker use and lung cancer survival. The...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Janick Weberpals, Lina Jansen, Walter E. Haefeli, Michael Hoffmeister, Martin Wolkewitz, Myrthe P. P. van Herk-Sukel, Pauline A. J. Vissers, Hermann Brenner
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a414ffc35a6946debb64e751c040ea6c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a414ffc35a6946debb64e751c040ea6c
record_format	dspace
spelling	oai:doaj.org-article:a414ffc35a6946debb64e751c040ea6c2021-12-02T12:32:32ZPre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort study10.1038/s41598-017-02913-82045-2322https://doaj.org/article/a414ffc35a6946debb64e751c040ea6c2017-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-02913-8https://doaj.org/toc/2045-2322Abstract Beta-blockers have been associated with decreased cancer mortality. However, evidence for lung cancer is sparse and reported beneficial effects might be based on biased analyses. In this so far largest study we investigated the association between β-blocker use and lung cancer survival. Therefore, patients with a lung cancer diagnosis between April 1998 and December 2011 were selected from a database linkage of the Netherlands Cancer Registry and the PHARMO Database Network. After matching eligible patients on the propensity score, adjusted hazard ratios (HRs) and corresponding 95% confidence intervals (CI) were calculated using Cox proportional hazards regression to investigate the association between pre-diagnostic and time-dependent β-blocker use and overall survival. Duration and dose-response analyses and stratified analyses by β-blocker type, histological subgroups and stage were conducted. Of 3,340 eligible lung cancer patients, 1437 (43%) took β-blockers four months prior to diagnosis. Pre-diagnostic β-blocker use was not associated with overall survival (HR 1.00 (0.92–1.08)) in the adjusted model. Time-dependent post-diagnostic analysis showed similar results with a HR of 1.03 (0.94–1.11). Trend analyses showed no association for cumulative dose (HR 0.99 (0.97–1.02)) and cumulative duration (HR 1.00 (0.96–1.05)). In conclusion, β-blocker use is not associated with reduced mortality among lung cancer patients.Janick WeberpalsLina JansenWalter E. HaefeliMichael HoffmeisterMartin WolkewitzMyrthe P. P. van Herk-SukelPauline A. J. VissersHermann BrennerNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Janick Weberpals Lina Jansen Walter E. Haefeli Michael Hoffmeister Martin Wolkewitz Myrthe P. P. van Herk-Sukel Pauline A. J. Vissers Hermann Brenner Pre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort study
description	Abstract Beta-blockers have been associated with decreased cancer mortality. However, evidence for lung cancer is sparse and reported beneficial effects might be based on biased analyses. In this so far largest study we investigated the association between β-blocker use and lung cancer survival. Therefore, patients with a lung cancer diagnosis between April 1998 and December 2011 were selected from a database linkage of the Netherlands Cancer Registry and the PHARMO Database Network. After matching eligible patients on the propensity score, adjusted hazard ratios (HRs) and corresponding 95% confidence intervals (CI) were calculated using Cox proportional hazards regression to investigate the association between pre-diagnostic and time-dependent β-blocker use and overall survival. Duration and dose-response analyses and stratified analyses by β-blocker type, histological subgroups and stage were conducted. Of 3,340 eligible lung cancer patients, 1437 (43%) took β-blockers four months prior to diagnosis. Pre-diagnostic β-blocker use was not associated with overall survival (HR 1.00 (0.92–1.08)) in the adjusted model. Time-dependent post-diagnostic analysis showed similar results with a HR of 1.03 (0.94–1.11). Trend analyses showed no association for cumulative dose (HR 0.99 (0.97–1.02)) and cumulative duration (HR 1.00 (0.96–1.05)). In conclusion, β-blocker use is not associated with reduced mortality among lung cancer patients.
format	article
author	Janick Weberpals Lina Jansen Walter E. Haefeli Michael Hoffmeister Martin Wolkewitz Myrthe P. P. van Herk-Sukel Pauline A. J. Vissers Hermann Brenner
author_facet	Janick Weberpals Lina Jansen Walter E. Haefeli Michael Hoffmeister Martin Wolkewitz Myrthe P. P. van Herk-Sukel Pauline A. J. Vissers Hermann Brenner
author_sort	Janick Weberpals
title	Pre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort study
title_short	Pre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort study
title_full	Pre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort study
title_fullStr	Pre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort study
title_full_unstemmed	Pre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort study
title_sort	pre- and post-diagnostic β-blocker use and lung cancer survival: a population-based cohort study
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/a414ffc35a6946debb64e751c040ea6c
work_keys_str_mv	AT janickweberpals preandpostdiagnosticbblockeruseandlungcancersurvivalapopulationbasedcohortstudy AT linajansen preandpostdiagnosticbblockeruseandlungcancersurvivalapopulationbasedcohortstudy AT walterehaefeli preandpostdiagnosticbblockeruseandlungcancersurvivalapopulationbasedcohortstudy AT michaelhoffmeister preandpostdiagnosticbblockeruseandlungcancersurvivalapopulationbasedcohortstudy AT martinwolkewitz preandpostdiagnosticbblockeruseandlungcancersurvivalapopulationbasedcohortstudy AT myrtheppvanherksukel preandpostdiagnosticbblockeruseandlungcancersurvivalapopulationbasedcohortstudy AT paulineajvissers preandpostdiagnosticbblockeruseandlungcancersurvivalapopulationbasedcohortstudy AT hermannbrenner preandpostdiagnosticbblockeruseandlungcancersurvivalapopulationbasedcohortstudy
_version_	1718394053170561024

Pre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort study

Ejemplares similares